Zacks Investment Research on MSN

Moderna stock on the move: What sparked the 13% jump in the past week?

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as ...

Moderna (MRNA) rockets 17% on strong preliminary FY25 results

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of ...

Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Blockonomi

Moderna (MRNA) Stock: Biotech Leader Surges 30% on Updated Guidance

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna Highlights 2025 Progress and Strengthened Vaccine Portfolio

An update from Moderna ( (MRNA) ) is now available.

Moderna expects $1.9 billion in sales, trims costs forecast for 2025

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its ...
Commercial Appeal

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This ...

What Analysts Are Saying About Moderna Stock

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...